Ultragenyx Pharmaceutical Inc. RARE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-9.61
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $673.0M | -$575.0M | — | -$472.0M | -$80.0M |
| 2024 | $560.0M | -$569.0M | — | -$421.0M | $255.0M |
| 2023 | $434.0M | -$607.0M | — | -$519.0M | $275.0M |
| 2022 | $363.3M | -$707.4M | — | -$496.6M | $352.0M |
| 2021 | $351.4M | -$454.0M | — | -$411.8M | $922.6M |
| 2020 | $271.0M | -$186.6M | — | -$176.1M | $1.2B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | director | 2026-06-15 | Sell | 2,000 | $25.05 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 2026-06-15 | Sell | 1,899 | $24.62 |
| Horn Howard | Chief Financial Officer | 2026-06-01 | Sell | 4,653 | $23.77 |
| SULIMAN SHEHNAAZ | director | 2026-05-18 | Sell | 5,740 | $25.12 |
| SULIMAN SHEHNAAZ | director | 2026-05-14 | Grant | 7,751 | — |
| Fust Matthew K | director | 2026-05-14 | Grant | 7,751 | — |
| Ray Amrit | director | 2026-05-14 | Grant | 7,751 | — |
| Sanders Corazon (Corsee) D. | director | 2026-05-14 | Grant | 7,751 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.61 (distress)
- Working capital / assets 0.37
- Retained earnings / assets -2.958
- EBIT / assets -0.349
- Equity / liabilities -0.05
Source: SEC EDGAR filings · CIK 0001515673 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.